{"schema_version":"1.0","type":"article","title":"諾華8,323人試驗受挫，心血管新藥的生意要怎麼重算？","url":"https://drugnews.com.tw/articles/2026-09-22-pelacarsen-horizon-topline-evidence.html","markdown_url":"https://drugnews.com.tw/articles/2026-09-22-pelacarsen-horizon-topline-evidence.md","lang":"zh-Hant","date":"2026-09-22","publish_at":"2026-09-22T08:00:00+08:00","updated_at":"2026-09-22","category":"商業分析系列","topic":"商業分析系列","tags":["Lp(a)","pelacarsen","HORIZON","Novartis","心血管","臨床試驗"],"summary":"Pelacarsen 的 Lp(a)HORIZON 三期試驗納入 8,323 名既有心血管疾病且 Lp(a) 升高病人，9 月 4 日初步公告顯示 Lp(a) 下降，但主要心血管終點未達標。這不是效果精確為零，也不是 Lp(a) 題材全盤失敗；9 月 4 日公告未列完整效果量、事件組成、預先指定族群與完整安全性資料。","key_points":[],"facts":[],"sections":[],"references":[],"images":[{"alt":"Lp(a) 降低屬於生物標記變化，主要心血管終點才是臨床結局；HORIZON 指標下降但主要終點未達標，不能解讀為效果精確為零。","url":"https://drugnews.com.tw/assets/articles/pelacarsen-horizon-topline-evidence/01_%E6%8C%87%E6%A8%99%E8%88%87%E7%B5%90%E5%B1%80_zh.png"},{"alt":"HORIZON 設計為 8,323 名已有心血管疾病且 Lp(a) 升高病人，隨機接受 pelacarsen 或安慰劑；這是試驗設計示意，不是結果分布。","url":"https://drugnews.com.tw/assets/articles/pelacarsen-horizon-topline-evidence/02_%E8%A9%A6%E9%A9%97%E8%A8%AD%E8%A8%88_zh.png"},{"alt":"目前已知的是初步結論與主要終點未達標；效果量、區間、事件分項與完整安全性仍待正式資料。","url":"https://drugnews.com.tw/assets/articles/pelacarsen-horizon-topline-evidence/03_%E5%B7%B2%E7%9F%A5%E8%88%87%E6%9C%AA%E7%9F%A5_zh.png"},{"alt":"下一份完整資料應看四件事：主要效果及不確定區間、絕對風險與事件組成、預先指定族群、安全性與資料完整度。","url":"https://drugnews.com.tw/assets/articles/pelacarsen-horizon-topline-evidence/04_%E4%B8%8B%E4%B8%80%E4%BB%BD%E6%95%B8%E6%93%9A_zh.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/pelacarsen-horizon-topline-evidence/01_%E6%8C%87%E6%A8%99%E8%88%87%E7%B5%90%E5%B1%80_zh.png","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-09-22）。諾華8,323人試驗受挫，心血管新藥的生意要怎麼重算？。https://drugnews.com.tw/articles/2026-09-22-pelacarsen-horizon-topline-evidence.html","disclaimer":"本文僅供產業研究與知識分享，不構成投資、醫療、募資或個股建議。","translations":{"en":"2026-09-22-pelacarsen-horizon-topline-evidence-en.html"},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}